

A<sup>2</sup>  
cont

% to about 20 % of CD34<sup>+</sup> stem cells, expressed with respect to the total number of progenitor cells.

Amend claim 6 as follows:

B<sup>1</sup>  
A<sup>3</sup>

--6. (Amended) Cell composition according to claim 2, wherein the macrophages, myeloid cells and the lymphocytes if present, are included in/or generated from blood mononuclear cells.

Amend claim 10 as follows:

B<sup>1</sup>  
A<sup>4</sup>

--10. (Amended) Process according to claim 8, comprising an additional step of macrophage activation, at the end of the coculture, for instance by addition of  $\gamma$ -interferon or muramyl peptides.

Amend claim 11 as follows:

B<sup>1</sup>  
A<sup>5</sup>

--11. (Amended) Process according to claim 7, comprising an additional step of concentration of the cells obtained at the end of the coculture, and resuspension in a vehicle suitable for administration to a patient.

Amend claim 13 as follows:

A<sup>6</sup> B<sup>1</sup>

--13. (Amended) Cell composition such as obtained according to the process of claim 7.

Amend claim 14 as follows:

A<sup>7</sup> B<sup>1</sup>

--14. (Amended) Pharmaceutical composition containing, as active substance, the cell composition according to claim 1.

Amend claim 15 as follows:

B1  
A8

~~15. (Amended) Cell composition according to claim 1, characterized by the fact that it is derived from and/or included in a peripheral blood mononuclear cell composition containing:~~

- ~~- from about 10 to about 50% of monocytes,~~
- ~~- from about 10 to about 70% of lymphocytes,~~
- ~~- from about 0,1 to about 20% of progenitor cells,~~
- ~~- from about 1 to about 50% of polynuclear cells,~~
- ~~- from about 0,1 to about 20% of stem cells.~~

Amend claim 16 as follows:

TO 211 255 9660  
G9

~~--16. (Amended) Use of a cell composition according to claim 1, for the preparation of drugs, for the restoration of hematopoiesis in an aplasic patient and/or the protection of patients against infectious diseases or against residual tumors.--~~

Add the following new claims:

B2  
A  
10

~~--17. (new) Cell composition according to claim 2, containing T lymphocytes, preferably in a ratio of about 10 to 60% expressed with respect to the total number of cells.~~

~~--18. (new) Pharmaceutical composition containing, as active substance, the cell composition according to claim 2.~~

~~--19. (new) Cell composition according to claim 2, characterized by the fact that it is derived from and/or~~

B 2  
included in a peripheral blood mononuclear cell composition containing:

- A 10  
cont
- from about 10 to about 50% of monocytes,
  - from about 10 to about 70% of lymphocytes,
  - from about 0,1 to about 20% of progenitor cells,
  - from about 1 to about 50% of polynuclear cells,
  - from about 0,1 to about 20% of stem cells.--
- 

09890652-112701